Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Newly diagnosed multiple myeloma, transplant-ineligible, drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Frail patients were excluded from the quadruplet trials and gain least from them.
Whether treatment can be fixed in duration or MRD-guided rather than continued until progression.
Nothing recorded yet.
Nothing recorded yet.
Background: MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶). Also on OnCo: Treatment journeys · Survivorship planner.
The cost of continuous antibody therapy for years in the largest myeloma population.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
MRD-neg 60.
PFS HR 0.
A milestone in how this cancer is treated.
Daratumumab, lenalidomide and dexamethasone improved progression-free and later overall survival over lenalidomide and dexamethasone in transplant-ineligible newly diagnosed myeloma; approved in June 2019.
A milestone in how this cancer is treated.